86 related articles for article (PubMed ID: 26883286)
1. Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer.
Seagle BL; Eng KH; Yeh JY; Dandapani M; Schiller E; Samuelson R; Odunsi K; Shahabi S
Sci Rep; 2016 Feb; 6():21591. PubMed ID: 26883286
[TBL] [Abstract][Full Text] [Related]
2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
3. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
4. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
5. Wnt Signaling and Survival of Women With High-Grade Serous Ovarian Cancer: A Brief Report.
Seagle BL; Dandapani M; Yeh JY; Shahabi S
Int J Gynecol Cancer; 2016 Jul; 26(6):1078-80. PubMed ID: 27327150
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
7. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
Lesnock JL; Richard SD; Zorn KK; Krivak TC; Beriwal S; Sukumvanich P; McBee WC; Kelley JL; Edwards RP
Gynecol Oncol; 2010 Mar; 116(3):345-50. PubMed ID: 19959211
[TBL] [Abstract][Full Text] [Related]
8. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
Wright AA; Cronin A; Milne DE; Bookman MA; Burger RA; Cohn DE; Cristea MC; Griggs JJ; Keating NL; Levenback CF; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland JC; Weeks JC; O'Malley DM
J Clin Oncol; 2015 Sep; 33(26):2841-7. PubMed ID: 26240233
[TBL] [Abstract][Full Text] [Related]
9. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
Kothari R; Nagel C; Koopmeiners JS; Ivy JJ; Geller M; Salani R; Argenta PA
Gynecol Oncol; 2010 Dec; 119(3):491-5. PubMed ID: 20888625
[TBL] [Abstract][Full Text] [Related]
10. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
11. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
[TBL] [Abstract][Full Text] [Related]
12. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.
Muntz HG; Malpass TW; McGonigle KF; Robertson MD; Weiden PL
Cancer; 2008 Aug; 113(3):490-6. PubMed ID: 18521923
[TBL] [Abstract][Full Text] [Related]
16. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
